resTORbio drops respiratory infection program as it looks ahead to Parkinson’s readout

reSTORbio discontinued development of RTB101 to prevent respiratory tract infections after it failed the pivotal PROTECTOR 1 trial, but the company is moving forward with the mTORC1 inhibitor in Parkinson’s disease and other age-related indications.

resTORbio Inc. (NASDAQ:TORC), a PureTech Health plc (LSE:PRTC) affiliate, lost most of its market value Friday, falling $6.86 (86%) to $1.09 for a market cap of $39.6 million, well below the company’s cash...